🚀 VC round data is live in beta, check it out!
VCANBIO Valuation Multiples
Discover revenue and EBITDA valuation multiples for VCANBIO and similar public comparables like Cofoe Medical, Tandem Diabetes Care, Weigao Group, SonoScape and more.
VCANBIO Overview
About VCANBIO
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Founded
1992
HQ
Employees
1.5K
Website
Financials (FY)
EV
$1B
VCANBIO Financials
VCANBIO reported last fiscal year revenue of $230M and EBITDA of $40M.
In the same fiscal year, VCANBIO generated $159M in gross profit, $40M in EBITDA, and $15M in net income.
VCANBIO P&L
In the most recent fiscal year, VCANBIO reported revenue of $230M and EBITDA of $40M.
VCANBIO expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $230M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $159M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 69% | XXX | XXX | XXX |
| EBITDA | — | XXX | $40M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Profit | — | XXX | $15M | XXX | XXX | XXX |
| Net Margin | — | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
VCANBIO Stock Performance
VCANBIO has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
VCANBIO's stock price is $3.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | -0.2% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVCANBIO Valuation Multiples
VCANBIO trades at 6.4x EV/Revenue multiple, and 36.3x EV/EBITDA.
VCANBIO Financial Valuation Multiples
As of April 6, 2026, VCANBIO has market cap of $2B and EV of $1B.
Equity research analysts estimate VCANBIO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VCANBIO has a P/E ratio of 116.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 36.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 49.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.2x | XXX | XXX | XXX |
| P/E | — | XXX | 116.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 46.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified VCANBIO Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
VCANBIO Margins & Growth Rates
VCANBIO's revenue in the last fiscal year declined by (0%).
VCANBIO's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
VCANBIO Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 1% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
VCANBIO Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cofoe Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Tandem Diabetes Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Weigao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| SonoScape | XXX | XXX | XXX | XXX | XXX | XXX |
| MicroPort | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VCANBIO M&A Activity
VCANBIO acquired XXX companies to date.
Last acquisition by VCANBIO was on XXXXXXXX, XXXXX. VCANBIO acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by VCANBIO
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVCANBIO Investment Activity
VCANBIO invested in XXX companies to date.
VCANBIO made its latest investment on XXXXXXXX, XXXXX. VCANBIO invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by VCANBIO
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout VCANBIO
| When was VCANBIO founded? | VCANBIO was founded in 1992. |
| Where is VCANBIO headquartered? | VCANBIO is headquartered in China. |
| How many employees does VCANBIO have? | As of today, VCANBIO has over 1K employees. |
| Is VCANBIO publicly listed? | Yes, VCANBIO is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of VCANBIO? | VCANBIO trades under 600645 ticker. |
| When did VCANBIO go public? | VCANBIO went public in 1993. |
| Who are competitors of VCANBIO? | VCANBIO main competitors are Cofoe Medical, Tandem Diabetes Care, Weigao Group, SonoScape. |
| What is the current market cap of VCANBIO? | VCANBIO's current market cap is $2B. |
| What is the current revenue of VCANBIO? | VCANBIO's last fiscal year revenue is $230M. |
| What is the current EV/Revenue multiple of VCANBIO? | Current revenue multiple of VCANBIO is 6.4x. |
| Is VCANBIO profitable? | No, VCANBIO is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.